Toregem BioPharma is developing TRG-035, an experimental antibody therapy designed to neutralize USAG-1, a protein that suppresses tooth formation, with the goal of reactivating dormant tooth buds and prompting natural tooth development. The company’s initial clinical focus is on patients with congenital tooth agenesis, with broader potential envisioned for stimulating a “third dentition” to treat tooth loss from aging, decay, or injury. Preclinical evidence of tooth regeneration has come primarily from animal studies (mice), while human testing to date has focused on safety. Toregem launched a Phase I trial at Kyoto University Hospital in October 2024 that enrolled 30 healthy adult men missing at least one molar; recruitment was reported to have stopped by March 2026 and the study is operationally complete, though full results have not been published. Toregem has secured a mix of equity financing and non-dilutive support (grants and subsidies) and reports cumulative funding above $29 million. The company is using its recent Pre-Series C proceeds to advance Phase II trials in Japan and to prepare for clinical development in the United States.

Total raised

$21M

Funding rounds

5

Latest round

Series C

Latest activity

May 2026